Research
Print page Print page
Switch language
Bispebjerg Hospital - a part of Copenhagen University Hospital
Published

Response to Biologics During the First Six Months of Therapy in Biologic-naïve Patients with Psoriasis Predicts Risk of Disease Flares: A Danish Nationwide Study

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Incidence of Kaposi Sarcoma in Sweden is Decreasing

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Management of Ocular Manifestations of Atopic Dermatitis: A Consensus Meeting Using a Modified Delphi Process

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Staphylococcus aureus Augments Release of Matrix Metalloproteinase-8 from Human Polymorpho-nuclear Leukocytes

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Skin Microbiome in Atopic Dermatitis

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Effectiveness and safety of switching from originator to biosimilar adalimumab in patients with psoriasis

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Inactivation of protoporphyrin IX in erythrocytes in patients with erythropoietic protoporphyria: A new treatment modality

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. A novel LC-MS/MS method to quantify eumelanin and pheomelanin and their relation to UVR sensitivity - A study on human skin biopsies

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Pretreatment with 5-Fluorouracil Cream Enhances the Efficacy of Daylight-mediated Photodynamic Therapy for Actinic Keratosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Nikolai Loft
  • Alexander Egeberg
  • Mads Kirchheiner Rasmussen
  • Lars Erik Bryld
  • Christoffer V Nissen
  • Tomas Norman Dam
  • Kawa Khaled Ajgeiy
  • Lars Iversen
  • Lone Skov
View graph of relations

Early response to treatment with biologics might be important for the stability of psoriasis and long-term outcome. The aim of this study was therefore to assess whether risk of flares and drug survival are associated with disease activity in the first 6 months of treatment of psoriasis with biologics. Biologic-naïve patients from the Danish nationwide registry, DERMBIO, were grouped based on absolute Psoriasis Area and Severity Index (PASI) during the first 6 months of treatment, as: PASI = 0, PASI > 0-≤2, PASI > 2-≤ 4, and PASI > 4. Among 1,684 patients, 746 achieved PASI= 0, 485 PASI > 0-≤2, 246 PASI > 2-≤4, and 207 PASI > 4. Longer flare-free period and drug survival were observed for patients with lower PASI in the first 6 months of treatment (adjusted hazard ratios for flares (95% confidence interval) with PASI=  0 as reference: PASI > 0-≤2 (1.35 (1.11-1.72]), PASI > 2-≤ 4 (2.32 [1.80-2.99]), and PASI > 4 (2.38 [1.80-3.15])). In conclusion, a low PASI in the first 6 months of treatment with biologics in biologic-naïve patients with psoriasis was associated with a more stable disease course, lower risk of flares, and longer drug survival.

Original languageEnglish
JournalActa Dermato-Venereologica
Volume101
Issue number1
Pages (from-to)adv00357
ISSN0001-5555
DOIs
Publication statusPublished - 4 Jan 2021

ID: 61760793